Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNA NASDAQ:QURE NASDAQ:SNDX NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$12.18-7.3%$10.05$5.00▼$16.85$769.11M1.51.59 million shs1.36 million shsQUREuniQure$13.69-1.7%$14.83$4.45▼$19.18$763.75M0.111.32 million shs1.06 million shsSNDXSyndax Pharmaceuticals$9.98+0.6%$9.88$8.58▼$22.50$853.59M0.741.75 million shs1.73 million shsTILInstil Bio$22.23-7.4%$27.97$9.85▼$92.00$157.41M2.16215,400 shs336,247 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks-7.04%-12.72%-3.87%+73.01%-19.87%QUREuniQure-1.65%-9.40%-4.13%-7.31%+78.72%SNDXSyndax Pharmaceuticals+0.60%+3.63%+10.89%-27.31%-56.04%TILInstil Bio-7.38%-29.85%-6.64%+53.52%+81.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNAGinkgo Bioworks1.1775 of 5 stars1.03.00.00.01.92.51.3QUREuniQure2.4186 of 5 stars3.52.00.00.01.82.50.6SNDXSyndax Pharmaceuticals3.5579 of 5 stars3.51.00.04.43.20.80.0TILInstil Bio3.0091 of 5 stars3.52.00.00.01.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 2.00Hold$8.50-30.21% DownsideQUREuniQure 2.91Moderate Buy$36.55166.95% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$34.10241.68% UpsideTILInstil Bio 3.00Buy$119.00435.31% UpsideCurrent Analyst Ratings BreakdownLatest TIL, SNDX, QURE, and DNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$47.007/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.007/15/2025SNDXSyndax PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$37.00 ➝ $35.007/10/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.006/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M3.14N/AN/A$13.17 per share0.92QUREuniQure$27.12M27.70N/AN/A($0.07) per share-195.57SNDXSyndax Pharmaceuticals$23.68M36.27N/AN/A$3.38 per share2.95TILInstil BioN/AN/AN/AN/A$25.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/7/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%N/ASNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)TILInstil Bio-$74.14M-$11.97N/AN/AN/AN/A-45.52%-29.23%8/12/2025 (Estimated)Latest TIL, SNDX, QURE, and DNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025N/ATILInstil Bio-$1.72N/AN/AN/AN/AN/A8/7/2025Q2 2025DNAGinkgo Bioworks-$1.44N/AN/AN/A$41.60 millionN/A8/7/2025Q2 2025SNDXSyndax Pharmaceuticals-$0.99N/AN/AN/AN/AN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 million5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/A5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A4.884.88QUREuniQure1.539.9811.99SNDXSyndax Pharmaceuticals1.535.805.75TILInstil Bio0.5830.3330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%QUREuniQure78.83%SNDXSyndax PharmaceuticalsN/ATILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%QUREuniQure4.79%SNDXSyndax Pharmaceuticals4.10%TILInstil Bio47.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableTILInstil Bio4106.56 million3.46 millionNo DataTIL, SNDX, QURE, and DNA HeadlinesRecent News About These CompaniesInstil Bio stock rises after positive data for cancer therapy in ChinaJuly 31 at 4:01 PM | za.investing.comInstil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US testJuly 31 at 4:01 PM | fiercebiotech.comFImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in ChinaJuly 31 at 6:00 AM | globenewswire.comUS FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumoursJuly 4, 2025 | pharmabiz.comPInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...July 3, 2025 | manilatimes.netMInstil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - NasdaqJuly 3, 2025 | nasdaq.comInstil Bio Shares Climb After FDA Clears Tumor Treatment ApplicationJuly 2, 2025 | marketwatch.comInstil Bio stock jumps after FDA clearance of IND applicationJuly 2, 2025 | in.investing.comInstil Bio Shares Surge on FDA Clearance for Investigational Cancer TherapyJuly 2, 2025 | msn.comInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsJuly 2, 2025 | globenewswire.comInstil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowJune 20, 2025 | zacks.comWall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetJune 16, 2025 | zacks.comInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramJune 11, 2025 | globenewswire.comAre You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceJune 4, 2025 | zacks.comInstil Bio appoints new Chief Medical OfficerJune 4, 2025 | uk.investing.comInstil Bio appoints Jamie Freedman as Chief Medical OfficerJune 2, 2025 | msn.comInstil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy DevelopmentJune 2, 2025 | quiverquant.comQInstil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerJune 2, 2025 | globenewswire.comInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 30, 2025 | globenewswire.comInstil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?May 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off3 Stocks to Cushion Your Portfolio This Earnings SeasonBy Chris Markoch | July 16, 2025View 3 Stocks to Cushion Your Portfolio This Earnings SeasonThe Bottom Is in for Kohl’s, But Let the Share Price Come to YouBy Thomas Hughes | July 23, 2025View The Bottom Is in for Kohl’s, But Let the Share Price Come to YouSnap-On: Snap Up This Strong Signal While It’s Still CheapBy Thomas Hughes | July 18, 2025View Snap-On: Snap Up This Strong Signal While It’s Still CheapTilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?TIL, SNDX, QURE, and DNA Company DescriptionsGinkgo Bioworks NYSE:DNA$12.18 -0.96 (-7.31%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$12.17 -0.01 (-0.08%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.uniQure NASDAQ:QURE$13.69 -0.23 (-1.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.21 +0.52 (+3.80%) As of 08/1/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Syndax Pharmaceuticals NASDAQ:SNDX$9.98 +0.06 (+0.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.12 +0.14 (+1.35%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Instil Bio NASDAQ:TIL$22.23 -1.77 (-7.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.22 -0.01 (-0.04%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
